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Abstract
Background: It is widely accepted by the scientific community that bioelectrical signals, which can be used for the
identification of neurophysiological biomarkers indicative of a diseased or pathological state, could direct patient
treatment towards more effective therapeutic strategies. However, the design and realisation of an instrument that
can precisely record weak bioelectrical signals in the presence of strong interference stemming from a noisy clinical
environment is one of the most difficult challenges associated with the strategy of monitoring bioelectrical signals
for diagnostic purposes. Moreover, since patients often have to cope with the problem of limited mobility being
connected to bulky and mains-powered instruments, there is a growing demand for small-sized, high-performance
and ambulatory biopotential acquisition systems in the Intensive Care Unit (ICU) and in High-dependency wards.
Finally, to the best of our knowledge, there are no commercial, small, battery-powered, wearable and wireless
recording-only instruments that claim the capability of recording electrocorticographic (ECoG) signals.
Methods: To address this problem, we designed and developed a low-noise (8 nV/√Hz), eight-channel, battery-
powered, wearable and wireless instrument (55 × 80 mm2). The performance of the realised instrument was
assessed by conducting both ex vivo and in vivo experiments.
Results: To provide ex vivo proof-of-function, a wide variety of high-quality bioelectrical signal recordings are
reported, including electroencephalographic (EEG), electromyographic (EMG), electrocardiographic (ECG),
acceleration signals, and muscle fasciculations. Low-noise in vivo recordings of weak local field potentials (LFPs),
which were wirelessly acquired in real time using segmented deep brain stimulation (DBS) electrodes implanted in
the thalamus of a non-human primate, are also presented.
Conclusions: The combination of desirable features and capabilities of this instrument, namely its small size (~one
business card), its enhanced recording capabilities, its increased processing capabilities, its manufacturability (since it
was designed using discrete off-the-shelf components), the wide bandwidth it offers (0.5–500 Hz) and the plurality
of bioelectrical signals it can precisely record, render it a versatile and reliable tool to be utilized in a wide range of
applications and environments.
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Background
Neuroelectrical activity in the brain generates oscillatory
bioelectrical signals, occurring in multiple frequency bands,
such as alpha (8–12Hz), beta (13–30Hz) and gamma (40–
80Hz) [1]. These oscillations result from the coordination
or synchronization of neural activity and have been linked
to a wide range of cognitive and perceptual processes [2].
However, they may also reflect abnormal function and
present as key biomarkers of many serious neurological dis-
orders, such as Parkinson’s disease (PD), epilepsy, traumatic
brain injury, schizophrenia and autism [3]. Such biomarkers
could improve the accuracy of diagnosis of the disease state
and facilitate the correct therapy. Thus, their identification
is becoming more and more crucial. Fig. 1 lists the fre-
quency bands where abnormal phase synchrony linked to
serious neurological disorders exists, and the percentage of
the population affected by each disease [1, 4, 5]. Significant
biomarkers that reveal the onset of severe diseases can be
extracted from bioelectrical signals (Table 1).
Recording of neurophysiological activity is an accepted
medical strategy for applications ranging from seizure mon-
itoring to neuroprosthesis [7]. Various techniques, each
with a different set of tradeoffs in terms of invasiveness,
spatial resolution and long-term quality and stability of
chronic recording, can be used to measure neuronal activ-
ity. Single-cell recording [7–10] provides high spatial reso-
lution, but at the expense of challenging requirements for
chronic electrode–tissue interface stability, the need for
preprocessing of information prior to its wireless transmis-
sion and increased amplifier power [7, 9–11]. Electroen-
cephalography offers minimally invasive recording, but at
the cost of limited spatial resolution, and the acquisition of
weak signals, vulnerable to environmental noise and mo-
tion/muscle artefacts [7, 11].
In other invasive biopotential acquisition techniques,
neural measurements are obtained, both on the surface
of the cortex (electrocorticographic/ECoG signals) [12,
13] and from a region around an implanted electrode
(LFPs). The advantage of these techniques is that they
are less susceptible to chronic measurement issues and
can thus offer more robust measurement of biomarkers
[7, 10, 11]. They are also less susceptible to artefacts en-
countered in externalized surface EEG recording setups
[7, 11]. Furthermore, ECoG and LFP signals encode bio-
markers related to epileptic seizures [14] and the spec-
tral decomposition of these signals can encode the
necessary information for implementing an effective
neuroprosthetic interface [11, 14, 15].
Increasing evidence suggests that the strength of LFP
oscillations in the beta frequency band (13–30Hz), which
can be consistently picked up in the subthalamic nucleus
(STN) of patients with PD, correlates with the severity of
the disease and the efficacy of therapy [16, 17]. However,
the last decade of LFP analysis also focused on spectral
power extraction from higher frequency bands, such as
Fig. 1 Frequency bands of abnormal phase synchrony characterizing serious neurological disorders [1, 4, 5]
Table 1 Biosignal characteristics [6]
Signal Bandwidth Amplitude Invasiveness
Spikes 100 Hz–10 kHz 50–500 μV Invasive
LFP 0.5–200 Hz 10 μV–1 mV Invasive
EEG 0.5–100 Hz 1–20 μV Non-invasive
ECoG 0.5–200 Hz 5–100 μV Moderately
invasive
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high gamma (60–80Hz) and 300 Hz (270–330 Hz) [18].
The power of these oscillations also correlates with PD
motor symptoms and clinical conditions, thus being eli-
gible as a biomarker [19].
Resonant neural response evoked by DBS, which is a
rapidly expanding treatment for neurological and psychi-
atric diseases, is a large-amplitude neural signal that fo-
cally appears in the STN. This response is greatest in the
dorsal region, which is the clinically optimal stimulation
target for PD, coincides with improved clinical perform-
ance, is chronically recordable, and is present under gen-
eral anesthesia [20]. These features render it as a readily
utilizable electrophysiological signal and a target-specific
biomarker that could potentially be used for guiding
electrode implantation surgery and optimizing DBS ther-
apy to improve patient outcomes [20]. Fasciculations,
which are random muscle twitches that can be observed
clinically, are of paramount importance in the diagnosis
of motor neuron diseases [21]. The exact origin of these
fasciculation potentials is unknown [21].
Aside from recording neuronal electrophysiological
signals, acquisition of non-neuronal biological signals is
also of paramount importance, especially in closed-loop
neurostimulation systems [22]. Taking into account the
dopaminergic-related origins of PD and biochemical
basis of other neuropsychiatric diseases, the concept of
integrating real-time biochemical assessments could be
useful for managing dynamic fluctuations in medication
effects [22]. Other non-neuronal biosignals which indi-
cate patient movement and clinical status in real-time
are peripheral physiological signals recorded using elec-
tromyographic techniques and signals recorded by non-
invasive accelerometers or gyroscopes [22].
In addition, electrocardiography examines changes in
cardiac electrical activity, e.g. rhythm disturbances, and
is thus considered to be a crucial diagnostic modality
[23, 24]. Finally, pulmonary veins (PV) play a major role
in triggering atrial fibrillation (AF) in humans but the
mechanisms underlying PV ectopy remain unclear [25].
Schauerte showed that it was possible to identify areas
in the atria that were richly innervated with autonomic
nerves, termed ganglionated plexi (GP), using high fre-
quency stimulation (HFS) through an endovascular ap-
proach [26]. Ablation of these GPs abolished these
effects [27–29]. Spontaneous PV ectopy, which is known
to trigger clinical AF, may be reduced by adjunctive
atrial autonomic ablation [25].
Taking into consideration that the identification of
new biomarkers related to serious diseases is of para-
mount importance, a crucial part of a medical diagno-
sis system is the monitoring of bioelectrical signals.
Nowadays, these signals are recorded routinely in the
clinic. However, patients have to cope with the prob-
lem of limited mobility because they are connected to
bulky and mains-powered instruments. This prevents
the continuous monitoring of patients, restricts the
signal acquisition time and deteriorates the diagnos-
tics of serious diseases. Hence, there is a growing de-
mand for small-sized, low-power and ambulatory
biosignal recording devices [30].
The initial focus of this work was to design and assess
a state-of-the-art analog front-end (AFE) that is able to:
a) offer an adequate passband and dynamic range for
recording a plethora of bioelectrical signals, b) success-
fully combine low power consumption with high per-
formance, c) interface with both low-impedance (e.g.
electrodes used in electroencephalography) and high-
impedance electrodes (e.g. segmented electrodes used
in DBS [31–33]), and d) provide accurate biosignal re-
cordings that can be used to investigate the existence of
possible biomarkers that characterize various diseases.
The ultimate aim was to use the afore-described versa-
tile and high-performance AFE as the fundamental
building block for producing a wearable and wireless
device that could be used by clinicians, either inde-
pendently or functionally integrated with existing med-
ical biosignal recording systems, to track a patient’s
clinical state.
Methods
Design requirements and implementation of the AFE
In order to achieve the goals specified in the introduc-
tion, a number of strict specifications for signal acquisi-
tion were imposed. These specifications are summarized
in Table 2. Clearly, a high gain and common mode re-
jection ratio (CMRR) along with low noise levels are re-
quired in order to ensure precise recordings of weak
bioelectrical signals. Moreover, a relatively wide dynamic
range in combination with adequate dc offset rejection
capabilities are required in order to prevent the output
of the instrument’s AFE from saturation caused by the
dc offsets stemming from the recording electrodes.
Table 2 Summary of key performance specifications related to
the AFE of the proposed instrument
Property Value Units/Comments
Gain ≥ 40 dB
Integrated noise ≤ 300 nVrms
(0.5 to 500 Hz)
CMRR ≥ 100 dB
DC tolerance ≥ 50 mV
Current consumption ≤ 5 mA
Input dynamic range ≥ ± 2 mV
Input impedance ≥ 1 GΩ
High-pass knee frequency 0.5 Hz
Low-pass knee frequency 500 Hz
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To meet the requirements for data acquisition, we de-
signed and implemented a biopotential recording AFE
architecture consisting of three main stages (Fig. 2): (i) a
differential pre-amplification stage with high-pass char-
acteristics; (ii) an active, 1st order high-pass filter that
enhances the dc offset rejection capabilities of the AFE;
and (iii) a passive, 2nd order low-pass filter that defines
the passband of the AFE and also serves as an anti-alias
filter for the analog-to-digital converter (ADC) stage,
which follows in the signal chain.
The pre-amplification stage consists of a low-noise in-
strumentation amplifier (INA) (model AD8422, Analog
Devices, USA). Taking into consideration that neural
signals, such as EEG signals and LFPs, are characterized
by very low amplitudes (typical range: 1–50 μV [16]), a
high CMRR in the front-end amplifier is required in
order to increase the signal-to-noise ratio (SNR) of the
recording instrument.
Next, to eliminate dc offsets originating from the
electrode-electrolyte/tissue interface [34], an active feed-
back integrator [35], which functions as a 1st order
high-pass filter with a knee frequency of 0.5 Hz, was in-
troduced in the front-end of the device. Crucially, this
engineering design decision along with the choice of
introducing a high gain (= 40 dB) on the front-end INA
chip, allows us to fully exploit the high CMRR offered by
the AD8422 INA chip (134 dB for a gain of 40 dB).
Moreover, since there is no passive filtering network
before the front-end amplifier and the gain of the
first stage is sufficiently high (equal to 40 dB) - thus
allowing the effective noise factor to be the noise fac-
tor of the first stage without an impact on the subse-
quent stages [36, 37] - the input-referred noise of the
designed AFE is expected to approximate the mea-
sured input-referred noise reported in the datasheet
of the AD8422 chip (≈ 8 nV/√Hz).
The second stage (see Fig. 2) includes an active 1st
order high-pass filter, which provides an amplification of
20 dB. The role of this filter is to enhance the dc offset
rejection capabilities of the overall AFE and offer the
additional gain required to better exploit the full scale
voltage range of the ADC (± 2.5 V). Finally, the strict
Fig. 2 Block diagram showing the overall AFE and the ADC section of the proposed instrument. The overall AFE consists of eight channels (five
channels on the main printed circuit board (PCB) of the instrument and another three channels on a stacked PCB that is adjusted on two headers
located on the main PCB). The biopotential recording AFE consists of three stages: (i) a differential pre-amplification stage with high-pass
characteristics, (ii) an active, 1st order high-pass filter that enhances the dc offset rejection capabilities of the AFE and (iii) a passive, 2nd order low-pass
filter that defines the passband of the AFE and also serves as an anti-alias filter for the ADC stage, which follows in the signal chain. The inputs of the
first five channels are differential, whereas the inputs of channels 6, 7 and 8 can either be differential or single-ended depending on the type of
biosignals (either amperometric or potentiometric or biopotential signals or a combination of them) the stacked PCB is intended to record
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area and power consumption requirements imposed on
the AFE design led to the introduction of a passive 2nd
order low-pass filter as the third stage of the AFE, because
it can be implemented with fewer components in com-
parison with an active low-pass filter of the same order.
Referring to Fig. 2, resistor R1 determines the gain of
the front-end INA, while resistor R2 and capacitor C1
determine the cut-off frequency of the 1st order high-
pass filter introduced in the first stage of the AFE. Next,
resistor R3 and capacitor C2 define the cut-off frequency,
while the ratio of resistors R4 and R5 define the gain
(1 + R5/R4) of the 1st order high-pass filter located in the
second stage of the AFE. Finally, resistors R6, R7 and ca-
pacitors C3, C4 determine the cut-off frequency of the
2nd order low-pass filter existing in the third (final)
stage of the AFE architecture.
The first stage (differential pre-amplification) is supplied
with ±5V to ensure that an adequate headroom is pro-
vided and eliminate the risk of saturation coming from
electrode dc offsets. However, the second stage (active
high-pass filter) is supplied with ±2.5 V to be able to inter-
face with the high-performance and low-power commer-
cial ADC chip (model ADS1298, Texas Instruments,
USA) that follows in the signal chain. The fundamental
building block for the design of the filtering stages is the
operational amplifier ADA4522 by Analog Devices. Fi-
nally, it should be noted that the resistors and capacitors
included in this three-stage AFE architecture are charac-
terized by a tolerance of 0.1 and 10% respectively.
As shown in Fig. 2, five recording channels of the pro-
posed instrument have been designed according to the
above-described AFE architecture (entitled “biopotential
recording AFE” in Fig. 2). These five channels culminate
in five out of eight channels of the ADC chip and can
record a wide variety of bioelectrical signals, such as
EEG, EMG, ECG, ECoG, LFP signals, PV ectopic activity
and evoked resonant neural activity (ERNA). Further-
more, the proposed instrument has been designed to
record some additional biosignals, such as acceleration
signals, which are recorded by an analog three-axis ac-
celerometer (ADXL335, Analog Devices, USA) located
on the instrument’s main PCB, or signals stemming
from amperometric and potentiometric biosensors,
which can be recorded by three auxiliary AFEs located
on a stacked PCB that is adjusted on the main PCB of
the instrument.
In other words, many types of stacked PCBs could be
designed, each one of them providing the ability to rec-
ord different types of bioelectrical signals (amperomet-
ric/potentiometric/biopotential). The nature of the
biosignals of interest would determine the type of the
stacked PCB to be placed on top of the main PCB. The
user can determine through software the type of bio-
signals (either acceleration signals or analog signals
stemming from the three auxiliary AFEs located on the
stacked PCB) to be digitized by the last three channels
of the ADC chip. At this point, it is important to clarify
that the addition of three low-power auxiliary AFEs (on
the stacked PCB) offers flexibility on the type of bio-
signals that can be recorded by the last three channels of
the ADC chip without significantly affecting the power
consumption of the overall system.
Finally, the above-described low-power three-axis
accelerometer, which is mainly intended to be used in
applications where tremor activity of patients with PD
or essential tremor needs to be monitored, is charac-
terized by an output sensitivity of 250 mV/g and a
noise of approximately 840 μgRMS (X, Y axis) and
1.7 mgRMS (Z axis) for an available bandwidth of 10
Hz. The reason behind the selection of a limited
bandwidth (= 10 Hz) for the acceleration measure-
ments lies in the fact that: a) tremor frequency of pa-
tients with PD ranges from 3 to 8 Hz [38] and b) the
lower the available bandwidth the better the reso-
lution of the accelerometer.
Architecture of the overall system
As shown in Fig. 3, the overall system consists of an 8-
channel AFE – illustrated in Fig. 2 - followed by the 8-
channel, simultaneous sampling, 24-bit, delta-sigma
ADS1298 chip, which further amplifies (the gain settings
of the built-in programmable gain amplifier are 1, 2, 3,
4, 6, 8, and 12 V/V), if required, and digitizes the analog
outputs of the biosignal recording channels. Next, a
field-programmable gate array (FPGA) module (Spartan
3e – 48MHz) controls the communication between the
ADS1298 chip and the radio transceiver, which is the
final stage of the system design.
Regarding wireless transmission, the communication
protocol that was selected for the wireless transmission
of the recorded data is the IEEE 802.15.4 protocol (the
AT86RF231 radio transceiver chip from Microchip
Technology was used) because: 1) similarly to Bluetooth
(IEEE 802.15.1), it is suitable for low data rate applica-
tions with limited battery power (such as portable,
battery-operated devices like the one presented in this
work), due to its low power consumption [39], and 2) it
offers extremely good bit error rate (BER) performance
at low SNRs [40] (the BER performance of the 802.15.4
transmission is between 7 and 18 dB better than that of
Bluetooth [40]), which is crucial since several radio ser-
vices exist in a typical clinical setting, where the pro-
posed instrument is intended to be used. Moreover, the
λ/4 monopole, 2.4 GHz antenna, which is characterized
by a length of 21 mm, a nominal gain of 0 dBi, an omni-
directional design and sub-miniature version A (SMA)-
plug fixing, was chosen since it combines small size, low
cost and high performance.
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The power supply section of the instrument includes a
high-efficiency, step-up DC-DC switching regulator
(LM2623, Texas Instruments, USA), which is suitable
for battery-powered and low input voltage systems. This
regulator converts the + 3.7 V supplied by the battery to
+ 5 V, which is required for the operation of the AFE
and the FPGA. Furthermore, the voltage regulator chip
TPS7A8001 (Texas Instruments, USA), the low-noise
regulated switched-capacitor voltage inverter LM27761
(Texas Instruments, USA) and the voltage converter
LM2662 (Texas Instruments, USA) provide all the volt-
age levels (± 2.5 V, + 3.3 V and - 5 V) required for proper
operation of the remaining parts of the device. The pro-
posed instrument is powered by a 1 Ah lithium battery
and can provide more than eight hours of continuous
wireless biosignal transmission. Finally, its size approxi-
mates the size of a business card (55 × 80mm2), as
shown in Fig. 4.
By carrying out the circuit design using discrete com-
ponents we reduce the barrier to manufacturing and
replication. Since these components are recommended
by their manufacturers for being used in medical instru-
mentation, their incorporation in the designs of medical
devices that are intended to be used in the clinic: 1)
maximizes the possibilities of successfully completing
the relevant clinical tests, and 2) enables a faster acquisi-
tion of the appropriate medical approvals, and thus a
faster launch into the market.
Regarding the research outcomes of our work, by
using (very high-performance) discrete components in
our design instead of designing an application specific
integrated circuit (ASIC), our aim is to provide a low-
noise instrument (with a noise performance that is bet-
ter than the noise performance provided by existing
devices, such as ASICs existing in the literature, com-
mercial devices and academic works based on discrete
off-the-shelf components) that can achieve a more
complete sampling of the physiomarker space. Next,
based on what is discovered, we can define a bespoke
ASIC that would provide the resolution required within
the power constraints of a miniaturized wireless device
(either implantable or just wearable).
The investigational character of our device also led us
to maintain the provided number of channels at a rela-
tively moderate level (=8). Since the wireless protocol we
use can support much larger data payloads than the one
we produce and transmit with the 8-channel architec-
ture, the best approach for increasing the channel count
of our device (if required) is to redesign the proposed in-
strument with more channels (≥16) and maintain the
single transmitter-single receiver system architecture. In
this way, challenges in the real-time character of the sys-
tem or data synchronization issues that may emerge in
architectures where multiple transmitters (with one or
more receivers) exist can be avoided.
Regarding the architecture of the receiver module (see
Fig. 3), it consists of: a) the AT86RF231 chip that re-
ceives the data transmitted by the proposed instrument,
b) an FPGA that can direct the data either to a PC
through the USB 2.0 interface that is provided by the
FPGA module (path (i) in Fig. 3), or to a commercially
available 16-bit digital-to-analog converter (DAC) chip
(AD5362, Analog Devices, USA - path (ii) in Fig. 3). The
analog output of the DAC chip can then be digitized
and depicted on the PC by a commercial data acquisi-
tion system (e.g. Powerlab 16/35 that is used in this
study). The second path (FPGA-DAC-Powerlab) was
added in the system architecture to ensure that our
Fig. 3 Block diagram showing the overall architecture of the proposed instrument. The data received by the receiver module can either be
directed i) to a personal computer (PC) through universal serial bus (USB) 2.0 interface, or ii) to a commercially available data acquisition system
(e.g. Powerlab) that digitizes and depicts the data on a PC. Path (ii) ensures that the proposed instrument can functionally integrate with existing
medical biosignal acquisition systems, if required
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instrument can functionally integrate with existing com-
mercial devices (e.g. Powerlab 16/35) and be used in
medical studies.
Design considerations for low-noise biosignal recordings
in a noisy clinical setting
As far as the noise sources at low frequencies are con-
cerned, it is well-accepted that the most important
source of electromagnetic interference (EMI) at low fre-
quencies is the 50 Hz noise from the mains. In order to
protect our system from the 50 Hz interference, we im-
plemented, cumulatively, the following strategy: a) the
device was always battery-powered during the experi-
ments to prevent the recorded biosignals from being
contaminated by the strong 50 Hz interference (and its
harmonics) stemming from the mains, b) an INA with a
high CMRR value (> 130 dB) and a high input imped-
ance (200 GΩ, 2 pF) was chosen to be the first stage of
the designed biopotential recording AFE. These two
features of the INA (high CMRR and input impedance
values) suppress interference originating from the mains,
c) the front-end INA further attenuates the 50 Hz noise
due to the inherent cancellation of even-order har-
monics it offers (since it’s a differential system).
As far as the noise sources at high frequencies are con-
cerned, in order to protect our system from high-
frequency EMI (e.g. radio frequencies, operating fre-
quencies of medical devices used in the clinic, such as
ultrasound, MRI devices etc) existing in the clinical set-
ting, we implemented, cumulatively, the following strat-
egy: a) a passive, 2nd order low-pass filter at 500 Hz was
placed in the AFE of our instrument. This filter signifi-
cantly attenuates high-frequency (>tens of kHz) noise
components, b) a passive, 1st order EMI (low-pass) filter
at 3MHz is included in the ADS1298 chip, which is the
ADC of our system. This filter further attenuates high-
frequency (>tens of MHz) noise components, c) a high-
performance INA with high CMRR values was placed at
Fig. 4 Structure of the proposed instrument. The instrument’s architecture includes: (a) a high-performance, eight-channel (five channels on the
main board and another three channels on a stacked PCB that is adjusted on the two headers shown in the picture) AFE, (b) an analog, low-
power 3-axis accelerometer, (c) an eight-channel, 24-bit ADC, (d) an FPGA module, (e) a 2 MBps Zigbee transceiver, and (f) a 2.4 GHz antenna
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the first stage of the designed AFE. As a result, high-
frequency noise components (present in the ambient en-
vironment) that appear as common-mode signals at both
inputs of this front-end INA are adequately suppressed
by its high CMRR (> 80 dB at 100 kHz), and d) during
the biosignal (ExG) acquisition experiments, the cables
that were used to connect the ExG electrodes to our re-
cording device were twisted (whenever practically pos-
sible) and wrapped in foil to minimize the effects of
noise on the recorded bioelectrical signals.
It should be clarified here that during all the exper-
iments (both ex vivo and in vivo) presented in this
paper, the PCB of our recording device was not
placed in any enclosure that could function as a Fara-
day cage (it was thus completely exposed to external
noise/EMI) in order to assess the worst case scenario.
Of course, in a real clinical setting a proper plastic
enclosure with EMI/RFI copper conductive coating
(that functions as a Faraday cage) has to be used to
host the designed PCB and protect the electronics
from external noise/interference sources (coating
manufacturers often specify an attenuation of more
than 75 dB from 1MHz to 1 GHz).
Results
In this section, a number of strict tests, which are per-
formed on the biopotential recording AFE to assess its
performance in terms of noise, linearity and temporal re-
sponse, are presented and analyzed. Furthermore, indica-
tive ex vivo recordings of EEG, ECG, EMG, acceleration
signals and fasciculations that were acquired from two
healthy subjects using the proposed instrument, are re-
ported. Moreover, in vivo recordings of weak LFPs,
which were wirelessly acquired in real time using DBS
electrodes implanted in the thalamus of a non-human
primate, are also presented. Finally, raw anonymized
data including extremely weak LFP signals, ERNA and
PV ectopic activity, which were previously recorded by
approved wired instruments during invasive experimen-
tal sessions are used to evaluate the performance of the
proposed instrument against high-performance commer-
cial biopotential acquisition systems. In this study, the
above-described raw anonymized data are presented to
the input of the instruments that are examined in each
series of experiments by means of a commercial wave-
form generator (Agilent 33220A).
The results shown in this section were derived from sig-
nal recordings that took place in a university laboratory,
which is vulnerable to noise/EMI originating from a wide
variety of devices that are in operation (e.g. servers, ultra-
sonic cleaners, air fume hoods, laboratory pumps for fluid
or gas transfer, a variety of automatic heating/cooling ele-
ments and systems, several other electric appliances such
as fridges etc). Similar comments hold for the in vivo
experiments reported here which took place at Newcastle
University in a high-tech space which can be characterized
as an ICU for non-human primates that contains a pleth-
ora of sized monitoring devices.
Additional experiments conducted in an active op-
erating theatre (Hammersmith Hospital, London, UK),
which is primarily used for cardiac interventions and
procedures, show that the instrument’s input-referred
noise levels remain unaffected when the instrument is
placed (again without making use of any enclosure
that could function as a Faraday cage) in a noisy clin-
ical environment. Hence, it is clear that the high
CMRR of our AFE in conjunction with the analog
(low-pass) filtering strategy followed in the AFE de-
sign of our device successfully suppress external EMI
and thus prevent noise from being coupled into the
physiological measurements. Finally, no 50 Hz inter-
ference was present in the amplitude spectrum of the
acquired noise recordings.
Transfer function and input referred noise
From the measured Bode magnitude plot shown in
Fig. 5a, it is clear that the proposed instrument’s AFE
provides a passband between 0.5 and 500 Hz and
achieves the desired gain of 60 dB. The roll-off of the
high- and the low-pass filters equals + 10 dB/Oct and −
40 dB/decade, respectively.
Since there is no passive filtering network before the
front-end AD8422 INA chip and the gain of the first stage
is sufficiently high (equal to 40 dB), the input-referred noise
of the designed AFE should approximate the measured
input-referred noise reported in the datasheet of the
AD8422 chip. The integrated noise of the proposed instru-
ment’s AFE over the frequency range 0.5–500Hz was mea-
sured and found to be equal to 169 nV rms. According to
Fig. 5b, the noise power spectral density estimate in the
passband for the designed AFE is 8 nV/√Hz, with the re-
sidual 1/f corner estimated roughly at 5Hz. Indeed, these
measured results are in agreement with the noise measure-
ments reported in the datasheet of the front-end AD8422
INA chip.
Total harmonic and intermodulation distortion
The measured total harmonic distortion (THD) plus
noise of the proposed instrument’s AFE (gain = 60 dB) is
presented in Fig. 6a. Taking into consideration that the
available dynamic range of the AFE is from 1 μV peak to
2.3 mV peak, it is clear that the achieved THD plus noise
is less than 0.3%. As shown in Fig. 6b, the third order
intercept point (IP3) of the proposed instrument’s AFE is
characterized by a desirable relatively high value (the
higher the IP3 values the more linear the amplifier and
the weaker the distortion products at its output).
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Fig. 6 Total harmonic distortion + Noise (a) and third order intermodulation distortion (IMD3) (b) of the proposed instrument’s AFE (gain = 60
dB). (a) Taking into consideration that the available dynamic range of the AFE is from 1 μV peak to 2.3 mV peak, it is clear that the achieved
THD + Noise is less than 0.3%. (b) The two tones applied to the AFE of the proposed instrument were f1 = 4.9 Hz and f2 = 5.1 Hz. The output
power of a single fundamental tone (in dBm - red line in the graph) and the relative power of the IMD3 products referenced to a single tone
(blue circles) are plotted against the applied input power. The third-order intercept line (dashed blue line) is extended to intersect the extension
of the fundamental output signal line (dashed red line). This intersection is termed the third order intercept point IP3. The calculated IP3 exhibits
a relatively high value, which is desired, since the higher the IP3 value the better the linearity of the amplifier and the weaker the output
intermodulation products that will be generated at the amplifier’s output
Fig. 5 Measured Bode magnitude plot (a) and input-referred noise (b) of the proposed instrument’s biopotential recording AFE. (a) The
biopotential recording AFE provides a passband between 0.5 and 500 Hz. The roll-off of the analog high- and low-pass filters equals + 10 dB/Oct
and − 40 dB/decade, respectively. (b) Noise power spectral density estimate in the passband for the biopotential recording AFE is 8 nV/√ Hz,
with the residual 1/f corner estimated at roughly 5 Hz
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Step and impulse response
The step response of a filter, which is the integral of the
impulse response, is useful in determining the envelope
distortion of a modulated signal [41]. The two most im-
portant characteristics of a filter’s step response are the
overshoot and the ringing. Overshoot must be minimal
for good pulse response and ringing must decay as fast as
possible, so that interference with subsequent pulses is
avoided. Transient response curves cannot provide a com-
pletely accurate estimation of the output since, in practice,
signals typically are not made up of impulse pulses or
steps. However, these curves constitute a convenient fig-
ure of merit so that transient responses of various filter
types can be compared on an equal footing [41].
The step response of our AFE (Fig. 7a), which initially
exhibits an undershoot of 250 μV, is free of ringing and
the impulse response (Fig. 7b) exhibits a relatively fast
settling. Another important test for evaluating the tem-
poral response of the designed AFE is to inject a bi-
phasic pulse to its input. As anticipated, the response of
our AFE to a biphasic pulse (see Fig. 7c) exhibits a sig-
nificantly faster settling in comparison to its impulse re-
sponse. In all cases, the theoretical responses (based on
the transfer function of the overall system – plotted in
solid green line in Fig. 7) approximate the measured
ones (plotted in solid black line in Fig. 7). Finally, it is
important to note here that the minimum slew rate
achieved by the front-end amplifiers of the proposed in-
strument is 0.8 V/μs.
Ex vivo recordings of ExG (EEG, EMG and ECG) signals
and fasciculations
In order to assess the low-noise recording capabilities of
the designed instrument, we recorded physiological sig-
nals that do not require invasive measurement tech-
niques and measured the achieved SNRs. Another
objective of these biosignal recordings was to show that
in spite of the high gain (60 dB minimum – 40 dB from
the front-end INA and another 20 dB from the active
high-pass filter existing at the 2nd stage of the biopoten-
tial recording AFE, see Fig. 2) and the relatively small
dynamic range (± 2.3 mV) that characterize the biopo-
tential recording AFE, it is capable of rejecting the dc
offsets coming from the electrodes and thus avoiding
saturation.
Fig. 7 (a) Step response, (b) impulse response and (c) response to a biphasic pulse, which characterize the proposed instrument’s AFE. (d) The
step response of the AFE, which initially exhibits an undershoot of 250 μV, is free of ringing (there is no decaying oscillatory activity after the
undershoot). (e) The impulse response of the AFE exhibits a relatively fast settling. (f) The response of the AFE to a biphasic pulse exhibits a
significantly faster settling in comparison to its corresponding impulse response (shown in (e)). In all cases, the output voltage (black line) is
presented after removing the gain of 60 dB that is applied by the biopotential recording AFE
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The measurement setup (Fig. 8) used in this series
of experiments allows for the comparison of the qual-
ity of signals recorded using two different methods.
In the first method (wired transmission), the signals
are recorded by the AFE of the proposed instrument
and are directly digitized and depicted on the com-
puter by a commercial instrument (Powerlab 16/35)
bypassing all the stages of the proposed instrument
located after its AFE (Fig. 8). In the second method
(wireless transmission), the signals are recorded and
digitized by the proposed instrument, are wirelessly
transmitted to the receiver module and are depicted
on the computer by the Powerlab 16/35 hardware.
This setup aims at confirming that the proposed in-
strument can functionally integrate with existing com-
mercial devices used in clinical studies and provide
faithful wireless transception. It is clear that this
setup can be perceived as the worst case scenario,
since, in the wireless communication method, the re-
corded biosignals have to be digitized by the pro-
posed instrument, converted back to analog from the
DAC of the receiver module and then digitized again
by the ADC of the Powerlab hardware.
One of the aims of these experiments was to record
alpha wave (7.5–12.5 Hz) activity, which is accepted as
the most prominent proof of an instrument’s capability
to measure EEG signals. The setup included three elec-
trodes, which were positioned as follows: 1. F3 – Ground
Electrode, 2. F4 – Reference Electrode, and 3. O2 – Re-
cording Electrode. In this test, an increased alpha wave
activity is expected to appear in the spectrum of the
EEG signals recorded when the subject’s eyes are closed.
In principle, EMG signals are recorded using either
minimally invasive or skin surface electrodes. For this
study, three skin surface disposable solid gel electrodes
(contact size 15 × 20 mm), produced by Unimed, were
placed at the following upper limb positions:
1. Palmaris longus muscle – Recording Electrode.
2. Metacarpal bones – Reference Electrode.
3. Proximal phalanx – Earth Electrode.
Regarding ECG signal acquisition, a simple three elec-
trode monitoring setup was prepared by using two elec-
trodes for active monitoring and a third one as ground
electrode [42]. The electrodes were used in lead I (RA-
LA) configuration leading to a bipolar signal acquisition.
The ground electrode was placed on the right leg ankle.
The electrodes used for the signal acquisition are the
Max-TAB resting electrodes (contact size 20 × 24mm),
produced by Unimed.
The ExG (EEG, EMG and ECG) signals, which are ex-
hibited in Fig. 9 after removing the applied gain of 60
dB, were recorded at 1 kSPS. Figure 9a illustrates a time-
domain EEG recording acquired using both of the previ-
ously described methods (wired and wireless). Regarding
the EMG measurement (Fig. 9b), the high amplitude sig-
nal was recorded while the subject was producing
tremor movements. Moreover, Fig. 9c shows that ECG
signals were successfully recorded. In order to examine
the performance cost introduced by the wireless trans-
mission method, the normalized root mean square error
(RMSE) between the time-domain recordings acquired
using the two methods (wired and wireless transmission
methods) was calculated and found to be equal to 1.7,
1.1 and 0.39% for the EEG, EMG and ECG measurement
setups, respectively. These errors can be considered tol-
erable taking into account that this experiment assesses
the above-described worst-case scenario.
Figure 9g, h and i illustrates the achieved SNR over
time during the EEG, EMG and ECG recording sessions,
respectively. It is clear that, during all recording sessions,
the achieved SNR values were higher than 25 dB. The
alpha waves test, presented in Fig. 10, shows that in the
band 7.5–12.5 Hz, the amplitude spectrum of the EEG
signals recorded when the eyes are closed is significantly
higher than the amplitude spectrum of the signals re-
corded when the eyes are open (Fig. 10a). The same con-
clusion is derived from Fig. 10b where alpha waves in
the band 7.5–12.5 Hz, during the eyes closed period, are
clearly visible.
Another important observation is that the amplitude
spectrums of the EEG signals recorded using the wired
Fig. 8 Measurement setup for comparing the quality of biosignals recorded using two different methods. In the first method (wired
transmission), the signals are recorded by the AFE of the proposed instrument and are directly digitized and depicted on the computer by a
commercial instrument (Powerlab 16/35). In the second method (wireless transmission), the signals are recorded by the proposed instrument, are
wirelessly transmitted to a receiver module and are depicted on the computer by the Powerlab 16/35 hardware
Petkos et al. Journal of NeuroEngineering and Rehabilitation          (2019) 16:156 Page 11 of 24
and wireless data transmission methods, not only ap-
proximate each other, but also they are in perfect agree-
ment with the amplitude spectrum recorded (at 1 kSPS)
by a high-performance commercial bioamplifier (Power-
lab 26 T, ADInstruments) (see Fig. 10a). This finding
suggests that the proposed instrument can provide reli-
able recordings even when its enhanced recording cap-
abilities are not fully exploited. Indeed, in both methods
adopted in this series of experiments (wired and wire-
less), the biosignals recorded by the proposed instru-
ment were finally digitized by the Powerlab 16/35
system, which provides 16-bit resolution for the analog-
to-digital conversion process (whereas our instrument
can provide 24-bit resolution, if used independently).
Finally, benign fasciculations have been recorded from
a healthy subject using the wireless transmission
method. The recorded fasciculations are shown in
Fig. 11. The electrodes that were used for this recording
session are the same with the ones used to record EMG
signals. Referring to Fig. 11, it is clear that the proposed
instrument can successfully record both weak and strong
fasciculations. Hence, it could be used as a research tool
to distinguish benign fasciculations and those related to
amyotrophic lateral sclerosis (ALS) on the basis of their
waveforms or firing characteristics [21]. It could also be
used as a wireless, home monitoring device for increas-
ing the biosignal acquisition time and thus enhancing
the diagnostics of ALS.
In vivo recordings of LFPs
To provide an in vivo proof-of-function, we recorded
LFPs from the thalamus of a non-human primate, at the
Fig. 9 Biosignal acquisition using the setup presented in Fig. 8. The applied gain was 60 dB and the sampling frequency was equal to 1 kSPS. (a)
Wired vs wireless EEG acquisition. (b) Wired vs wireless EMG acquisition from the palmaris longus muscle. (c) Wired vs wireless ECG acquisition.
(d) Detailed view of the wireless and wired time-domain EEG recordings. (e) Detailed view of the wireless and wired time-domain EMG
recordings. (f) Detailed view of the wireless and wired time-domain ECG recordings. (g) The SNR of the EEG signals was measured and found to
be continuously higher than 25 dB. (h) The SNR of the EMG signals was measured and found to be continuously higher than 25 dB. (i) The SNR
of the ECG signals was measured and found to be continuously higher than 30 dB
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Fig. 10 (a) Amplitude spectrum (the reference level of amplitudes equals 1 V) of EEG signals recorded by the proposed instrument when the
subject’s eyes are open and when they are closed. A high-performance commercial bioamplifier (Powerlab 26 T, ADInstruments) was also used as
a reference instrument in this series of experiments. It is clear that in the 7.5–12.5 Hz band the amplitude spectrum of the EEG signals recorded
when eyes are closed is significantly higher than the amplitude spectrum of the signals recorded when eyes are open. Furthermore, the results
acquired using the wireless transmission method: 1) are in full agreement with the results acquired using the wired transmission method, and 2)
are in full agreement with the results acquired using the commercial bioamplifier. (b) EEG spectrogram calculated from the EEG data wirelessly
recorded by the proposed instrument. Alpha waves in the 7.5–12.5 Hz band during the eyes closed period are clearly visible
Fig. 11 Wireless recording of benign fasciculations
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end of a non-recovery procedure that was performed for
the primary purpose of another ongoing study. A female
rhesus macaque was anesthetised with a ketamine/mid-
azolam/alfentanil infusion and a segmented DBS elec-
trode (electrode A, model DB-2201, Boston Scientific
Neuromodulation) was implanted into the thalamus as
shown in Fig. 12. LFP signals were differentially recorded
through contacts 1 and 3 of electrode A (illustrated as
A1 and A3 in Fig. 12, respectively). The non-human pri-
mate was under anaesthesia during the entire experi-
ment with the head held in a primate stereotactic frame,
which was connected to the ground of the recording
system. The LFP signals recorded by our instrument
were digitized at a sampling frequency of 1 kSPS and
were wirelessly transmitted to the receiver module.
Then, they were depicted on a computer by the
Powerlab data acquisition system (wireless transmis-
sion method - described in Fig. 8). As shown in
Fig. 13, the proposed instrument can wirelessly pro-
vide low-noise recordings of weak LFP signals in a
noisy animal clinic environment.
Recording of resonant neural response
In this experiment, a signal segment containing ERNA
recorded by a dc-coupled commercial instrument from
the STN at 2048 SPS, was injected at the instrument’s
biopotential recording AFE by a commercial waveform
generator (Agilent 33220A). The temporal response of
the proposed instrument is shown in Fig. 14a. The main
aim of this experiment was to ensure that: 1) no over-
shoot or ringing is produced by the ac-coupled AFE of
the instrument as a response to DBS, and 2) the instru-
ment’s AFE can reliably record the decaying oscillatory
activity that characterizes the evoked potentials recorded
from the STN. Indeed, our biopotential recording AFE
exhibits a fast and free from any overshoot or ringing ef-
fects transient response to the stimulation pulses (see
Fig. 14c). Hence, it can successfully record the ERNA of
interest, which is considered to be the signal that ap-
pears 4 msec after the last DBS pulse and lasts for 20
msec in total (dotted rectangle in Fig. 14c) [20].
Recording of PV ectopic activity
In this experimental procedure, a signal that contains
HFS pulses and ectopic activity (represented by a solid
blue line in Fig. 14b) was injected to the input of the
proposed instrument by a waveform generator (Agilent
33220A). This signal was previously recorded (in bipolar
mode from a catheter placed in the coronary sinus)
using a commercially available wired and dc-coupled
medical device with the sampling frequency set at 1
kSPS. Our instrument sampled the input signal at 1
kSPS and wirelessly transmitted it to the receiver mod-
ule (wireless transmission method).
The temporal response of the proposed instrument
with (solid red line) and without (solid black line) the
application of a real-time digital high-pass filter at 30 Hz
is presented in Fig. 14b. Clearly, the ac-coupled AFE of
the proposed instrument exhibits a fast transient re-
sponse (solid black line), which allows it to recover very
quickly from the saturation state (+ 2.5 mV) it reached
due to the high-amplitude HFS pulses and thus record
the ectopic activity of interest. Moreover, as shown in
Fig. 14d, a digital high-pass filter applied on the signal
recorded by the proposed instrument rejected in real-
time the dc offset induced by stimulation, producing an
output (solid red line) that approximates the signal re-
corded by the commercial dc-coupled medical device.
Fig. 12 Experimental setup for evaluating the recording capabilities of the proposed instrument in vivo. A DBS electrode (electrode A, model DB-
2201, Boston Scientific Neuromodulation) was implanted into the thalamus of an anaesthetised non-human primate. LFP signals were
differentially recorded through contacts 1 and 3 of electrode A. The non-human primate was under anaesthesia with the head held in a primate
stereotactic frame, which was connected to the ground of the recording system. The LFP signals were digitized by our instrument at a sampling
frequency of 1 kSPS and were wirelessly transmitted to the receiver module (wireless transmission method – described in Fig. 8)
Petkos et al. Journal of NeuroEngineering and Rehabilitation          (2019) 16:156 Page 14 of 24
This measured result suggests that the application of a
digital high-pass filter can significantly enhance the dc
offset suppression capabilities of the AFE and increase
the quality of the recorded signals. It is important to
note here that the AFE of the commercial medical de-
vice also saturated during HFS because its maximum dy-
namic range was set by the clinicians at ±5 mV so that a
sufficiently high gain is ensured.
Recording of acceleration signals
In this experiment, acceleration signals recorded by the
accelerometer located on the main PCB of the proposed
instrument, were digitized at 1 kSPS and were wirelessly
transmitted to the receiver module (wireless transmis-
sion method). Figure 15 shows the acceleration signals
recorded during three separate sessions. During the first
session, movements of the proposed instrument’s PCB,
where the accelerometer is located, were produced on
the x-axis for a duration of approximately 9 s (Fig. 15a).
During the second session, movements of the proposed
instrument’s PCB were produced on the y-axis for a dur-
ation of approximately 9 s (Fig. 15b). During the third
session, movements of the proposed instrument’s PCB
were produced on the z-axis again for a duration of ap-
proximately 9 s (Fig. 15c). In all recording sessions, the
instrument started from immobility and at the end of
the produced movements it returned back to immobility.
Clearly, under all examined circumstances (tremor
movements in X, Y and Z axes), the accelerometer was
able to successfully discriminate the state of immobility
from the state where tremor occurs.
Comparison with other biosignal acquisition systems
The aim of the series of tests presented in this sec-
tion was to compare the performance of the designed
biopotential recording AFE with a commercial high-
gain differential amplifier (model DP-301, Warner in-
struments) by injecting extremely weak biosignals to
their inputs. More specifically, LFP signals were
injected to the inputs of the two AFEs by a waveform
generator (Agilent 33220A) and the quality of the
output signals was assessed in both time and fre-
quency domains. In the time domain, the normalized
RMSE between the output of each AFE and the ori-
ginal LFP signal was used to evaluate the quality of
biosignal recording. The normalization for the RMSE
calculation was performed over the range of the refer-
ence signal, which is the original LFP signal.
In order to compare the two AFEs on an equal footing,
their analog outputs were digitized by the same ADC
(ADC of the Powerlab 16/35 system, which provides a
16-bit resolution) at 1 kSPS. Next, a third device was
Fig. 13 (a) Differential LFP recordings acquired from the thalamus of an anaesthetised non-human primate with the experimental setup
illustrated in Fig. 12. (b) A detailed view of the recorded LFPs reveals their small amplitudes (< 20 μV peak). (c) Amplitude spectrum of the
recorded LFPs. Clearly, the proposed instrument can wirelessly provide low-noise recordings of weak LFP signals in a noisy clinical environment
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introduced in the measurement setup (Bioamplifier/
Powerlab 26 T) to record the same LFPs at 1 kSPS.
The role of this device was to act as an independent
reference instrument that is optimized for measuring
weak bioelectrical signals such as EEG signals. The
analog high-pass filters included in the DP-301 ampli-
fier (cut-off frequency at 1 Hz) and the bioamplifier
(cut-off frequency at 0.5 Hz) were activated so that
their temporal responses can be compared with the
temporal response of the proposed instrument’s ac-
coupled AFE (cut-off frequency at 0.5 Hz) on an equal
footing. Moreover, the gain of the DP-301 amplifier
was set at 60 dB so that it is equal with the gain in-
troduced by the biopotential recording AFE. Finally,
the resolution of the reference instrument (bioampli-
fier/Powerlab 26 T) was set at ±100 μV (minimum
available) during the LFP signal recording sessions.
The measurement setup is shown in Fig. 16.
Referring to Fig. 17a and c, it is clear that the output
of the proposed instrument’s AFE better tracks the
changes occurring in the LFP signal presented at its in-
put in comparison to the other two instruments. This is
verified by the fact that the normalized RMSE between
the original LFP signal and the signal recorded from the
proposed instrument’s AFE is less than the errors char-
acterizing the other two instruments. More specifically,
the RMSE values that characterize the proposed instru-
ment, the DP-301 amplifier and the bioamplifier are
equal to 4, 4.1 and 4.9%.
According to the amplitude spectrum shown in
Fig. 17b and d, the AFE of the proposed instrument pro-
vides accurate recording of the LFP signal, whereas the
other two instruments cannot accurately record the fre-
quencies of the LFP signal that are higher than 120 Hz.
It is important to stress here that a significant portion of
the calculated RMSE values can be attributed to the fact
Fig. 14 (a) Temporal response of the proposed instrument’s AFE when a signal segment containing ERNA, recorded by a dc-coupled
commercial instrument from the STN at 2048 SPS, is injected to the instrument’s AFE. The signal was recorded by the instrument’s AFE
and was then digitized by the Powerlab hardware at 4 kSPS (wired transmission method). (b) Temporal response recorded by the
proposed instrument with and without the application of a real-time digital high-pass filter at 30 Hz when a signal that contains high-
frequency stimulation (HFS) pulses and ectopic activity was injected to the biopotential recording AFE’s input by a waveform generator
(Agilent 33220A). The signal was sampled by means of our instrument at 1 kSPS, was wirelessly transmitted to the receiver module and
was depicted on the computer using the Powerlab 16/35 hardware (wireless transmission method). (c) Detailed view of the successfully
recorded ERNA of interest. (d) Detailed view of the successfully recorded ectopic activity. It is clear that the application of a digital high-
pass filter enables real-time recording of a high-quality signal, which approximates the signal recorded by the dc-coupled commercial
medical device
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that four attenuators that provided 70 dB attenuation
were used in order to bring the amplitude of the LFP
signal injected by the waveform generator down to the
level that characterizes the original LFP signal, which is
approximately equal to 10 μV peak.
Furthermore, Fig. 18a exhibits the amplitude spectrum
of the output voltage recorded from the AFE of the pro-
posed instrument (black line), the DP-301 differential
amplifier (red line) and the bioamplifier included in the
Powerlab 26 T data acquisition system (pink line) when
two sinusoidal single tones (5 Hz and 25 Hz, amplitude
100 nV peak) were injected sequentially to the inputs of
the instruments and were sampled at 1 kSPS. To push
the limits of the recording capabilities of the three in-
struments towards their noise floors, two weak sinus-
oidal single tones (5 Hz and 25 Hz, amplitude 30 nV
peak) were injected sequentially to the inputs of the in-
struments and were also sampled at 1 kSPS (Fig. 18b).
Referring to Fig. 18c and d, it is clear that the AFE of
the proposed instrument and the bioamplifier can accur-
ately record both of the weak sinusoidal tones presented
at their inputs, whereas the DP-301 differential amplifier
detected the tones but it did not provide an accurate re-
cording. Furthermore, Fig. 18 clearly shows that the
noise floor of the proposed instrument is lower than the
noise floors of the other two instruments. A comparison
Fig. 16 Recording of LFPs injected by a waveform generator (Agilent 33220A) to the inputs of: a) the proposed instrument’s AFE, b) a
commercial high-gain differential amplifier (model DP-301, Warner instruments), and c) a very high-performance commercial bioamplifier
(Powerlab 26 T, ADInstruments)
Fig. 15 Time-domain profiles of acceleration signals recorded during three separate sessions. (a) during the first session, movements of the
proposed instrument’s PCB, where the accelerometer is located, were produced along the x-axis for a duration of approximately 9 s (b) during
the second session, movements of the proposed instrument’s PCB were produced along the y-axis for a duration of approximately 9 s (c) during
the third session, movements of the proposed instrument’s PCB were produced along the z-axis for a duration of approximately 9 s. In all
recording sessions, the instrument started from immobility and at the end of the produced movements it returned back to immobility. Clearly,
under all examined circumstances (tremor movements in X, Y and Z axes), the accelerometer was able to successfully discriminate the state of
immobility from the state where tremor occurs
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of the proposed instrument’s capabilities against the
ones provided by the other two devices (DP-301 ampli-
fier and Powerlab 26 T) is drawn in Table 3.
Another important factor that needed to be examined
was the latency added by the wireless transmission
method for the wireless transmission of eight channels
of data. This latency was measured and found to be ap-
proximately equal to 1 msec. It is attributed to the time
required for the wireless transmission (= 512 μsec) and
the time needed for the serial peripheral interface (SPI)
communication between the other blocks of the instru-
ment’s design. More specifically, 36 μsec are needed for
the ADS1298-FPGA communication, 107 μsec for the
FPGA-Tx communication, 36 μsec for the Rx-FPGA
communication and finally another 32 μsec for the
FPGA-DAC communication (in total 723 μsec).
Moreover, we have confirmed the integrity and reliability
of the wireless biosignal recordings for a distance be-
tween the proposed instrument and the receiver module
up to 5 m. Finally, it should be noted here that no diffi-
culties were observed in normal operation of our system
when the wearable/wireless device and the receiver mod-
ule were placed in two different adjacent rooms that
were separated by a wall.
A comparison of the proposed instrument with (port-
able and implantable) wireless commercial biopotential
acquisition systems is given in Table 4. This work dem-
onstrates the highest CMRR and input impedance, the
lowest input referred noise and smallest size among the
state-of-the-art instruments presented in this table.
Moreover, compared to the TMSI Mobita device, it can
provide 8 h of continuous operation (continuous wireless
Fig. 17 (a) Recording of LFPs. The original LFP signal, which was previously recorded from the STN in a patient with PD withdrawn from
levodopa, was injected by a waveform generator (Agilent 33220A) to the inputs of the proposed instrument’s AFE, the DP-301 differential
amplifier and the bioamplifier included in the Powerlab 26 T data acquisition system. (b) Amplitude spectrum of the signals presented in Fig. 17
(a). (c) The output of the proposed instrument’s AFE better tracks the changes occurring in the original LFP signal in comparison to the other
two instruments. This is verified by the fact that the RMSE between the original LFP signal and the signal recorded by the proposed instrument’s
AFE is less than the errors characterizing the other two instruments. (d) The detailed amplitude spectrum shows that the AFE of the proposed
instrument provides accurate recording of the LFP signal, whereas the other two instruments cannot accurately record the frequencies of the LFP
signal that are higher than 120 Hz
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Fig. 18 (a) Amplitude spectrum of the output voltage recorded from the AFE of the proposed instrument, the DP-301 Warner differential
amplifier and the bioamplifier included in the Powerlab 26 T data acquisition system when two sinusoidal single tones (5 Hz and 25 Hz, amplitude
100 nV peak) were injected sequentially to the inputs of the instruments. The outputs of the three instruments were sampled at 1 kSPS. (b)
Amplitude spectrum of the output voltage recorded from the thee instruments when two sinusoidal single tones (5 Hz and 25 Hz, amplitude 30
nV peak) were injected sequentially to the inputs of the instruments. The outputs of the three instruments were sampled at 1 kSPS. (c) It is clear
that the AFE of the proposed instrument and the bioamplifier can accurately record the weak sinusoidal tone, whereas the DP-301 differential
amplifier detects the tone but it cannot provide an accurate recording. (d) As in the case of the 100 nV peak sinusoidal tone, only the AFE of the
proposed instrument and the bioamplifier can precisely record the 30 nV peak sinusoidal tone. It is important to note here that the noise floor of
the proposed instrument is lower than the noise floors of the other two instruments
Table 3 Comparison of the proposed instrument with the Warner amplifier and the bioamplifier included in Powerlab 26 T
Parameters Warner amplifier Bioamp in Powerlab 26 T This work
Number of channels 1 2 5 (+ 3)
Type of biosignals EEG, ECG, extracellular spikes ECG, EMG, EEG ExG, ECoG, LFP, ERNA, body position
and movement, PV ectopic activity
(+ amperometric/potentiometric)
Supply of the ADC – ±10 V ±2.5 V
Voltage gain 40–80 dB 54–100 dB 60 dB
Input voltage range ±1mV to ±100 mV ±100 μV to ±20mV ±2.3 mV
Maximum available bandwidth DC to 10 kHz Full bandwidth 0.5–500 Hz
Input impedance 1000 GΩ 100 MΩ 200 GΩ
Input referred noise 1.52 μV rms
(1 Hz-10 kHz)




DC tolerance ±3 V ±300mV ±85mV
CMRR 100 dB 110 dB 134 dB
Maximum resolution of the ADC Purely analog output 16 bits 24 bits
Maximum sampling frequency Purely analog output 100 kSPS 1 kSPS (32 kSPS for wired)
Hours of continuous operation 200 (4 batteries 9 V) Mains powered 8 (1 Ah lithium battery)
Wireless capability No No Yes (Zigbee)
Area (length × width) 350 cm2 500 cm2 44 cm2 (PCB area)
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transmission of all eight channels of the simultaneous-
sampling ADC included in our instrument) with a smaller
lithium battery. This is attributed to the fact that Mobita
uses the Wi-Fi protocol for wireless data transmission,
which allows for a higher maximum sampling rate (2000
SPS) at the expense of higher power consumption and
shorter battery life. It is important to highlight here that,
to the best of our knowledge, there are no commercial,
small, battery-powered, wearable and wireless recording-
only instruments that claim the capability of recording
ECoG signals. As shown in Table 4, it is clear that, com-
pared to high-performance bidirectional interface systems
(such as the Activa PC + S neurostimulator from Medtro-
nic), which are widely used in applications that include
concurrent sensing and closed-loop neurostimulation, our
instrument is better suited for applications where multi-
channel (> 4 channels) and high-resolution (> 10 bits)
ECoG recording (without stimulation) is required.
Moreover, a comparison of the proposed instrument
with other state-of-the-art wearable and wireless biopo-
tential acquisition systems that exist in the literature and
also use discrete (commercial) components as building
blocks is performed in Table 5. These systems can record
biopotential signals of a specific type by using either com-
mercial analog front-end chips (e.g. the Intan RHD2132
chip in [43] or the ADS1299 chip in [44]) or commercially
available components to build application-specific analog
front-ends (e.g. in this work and in [45]). It is clear that
our instrument achieves a noise performance that is sig-
nificantly better than the noise performance provided by
the other three devices. It is important to emphasize here
that although two of the devices presented in Table 5 (in
[44, 45]) offer lower bandwidth than our device, they still
provide an integrated noise value that is higher than the
one offered by our instrument. The versatility of our AFE
architecture and the real-time wireless biosignal transmis-
sion it can offer at 1 kSPS sampling frequency allows the
proposed instrument to record a wider variety of bio-
signals compared to the other systems, with the lowest
wireless transmission latency. In addition, it offers the
highest input impedance, which allows it to efficiently
interface with high-impedance electrodes (e.g. segmented
electrodes in DBS), and the highest CMRR value, which
can be very useful in applications where large common-
mode disturbances (stemming from the application of
strong stimulation pulses in simultaneous biosignal re-
cording and stimulation setups) have to be rejected. The
remaining features of our device are equally good or com-
parable to the features of the other wearable and wireless
systems presented in Table 5.
Table 4 Comparison of the proposed instrument with commercial (portable and implantable) wireless biopotential acquisition
systems
Parameters TMSI Mobita TMSI Mobi Activa PC + S This work
Number of channels 32 6 (+ 4) 2 5 (+ 3)





LFP/ECoG ExG, ECoG, LFP, ERNA, body
position and movement, PV
ectopic activity (+ amperometric/
potentiometric)
Supply of the ADC ±2 V ±2 V 1.7–2.2 V ±2.5 V
Voltage gain 20 dB 26 dB 48–66 dB 60 dB
Input voltage range ±200 mV ±100mV ±500 μV to ±4.4 mV




DC up to 0.13 × sample
frequency
– 0.5–260 Hz 0.5–500 Hz
Input impedance > 100 MΩ > 100 MΩ – 200 GΩ
Input referred noise < 0.4 μV rms (0.1–10 Hz) < 1 μV rms < 1 μV rms 0.169 μV rms (0.5–500 Hz)
DC tolerance – – – ±85mV
CMRR > 100 dB > 90 dB > 80 dB 134 dB
Maximum resolution
of the ADC
24 bits 24 bits 10 bits 24 bits
Maximum sampling
frequency
2000 SPS 2048 SPS 422 SPS 1 kSPS (32 kSPS for wired)
Hours of continuous
operation
6 to 8 (4.1 Ah lithium battery) - (2 AA batteries) – 8 (1 Ah lithium battery)
Wireless capability Yes (Wi-Fi) Yes (Bluetooth) Yes (175 kHz near-field
inductive)
Yes (Zigbee)
Area (length × width) 105 cm2 112 cm2 39 cm2 44 cm2 (PCB area)
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Finally, a comparison of our AFE with state-of-the-art
ASICs for biopotential signal acquisition is given in
Table 6. As anticipated, a tradeoff exists between ultra-
low power consumption (state-of-the-art ASICs) and su-
perior noise performance (proposed instrument’s AFE).
Discussion
The system architecture validated in this study ad-
dresses several of the major challenges to the devel-
opment of a small, high-precision, battery-powered,
wireless and wearable multi-instrument that is
intended to be used in the ICU or in a High Depend-
ency Unit, or in patient home monitoring studies. A
difficult task when designing a biopotential acquisition
AFE that is intended to be used in a clinical setting,
is to ensure that it can provide real-time biosignal re-
cordings. This real-time character is particularly im-
portant for neuromodulation because the stimulation
must change in real time based on the measured state
of the neural network [16].
Table 5 Comparison of the proposed instrument with other state-of-the-art wearable and wireless biopotential acquisition systems
existing in the literature
Parameters [43] [44] [45] This work
Number of channels 32 8 4 5 (+ 3)





Voltage gain 46 dB ≈ 28 dB (max) ≈ 54 dB 60 dB
Input voltage range ±5mV ±100mV ±1.15 mV ±2.3 mV
Maximum available
bandwidth
10–500 Hz 0–250 Hz 1.5–100 Hz 0.5–500 Hz
Input impedance 1.3 GΩ (10 Hz) ≈ 620 MΩ (10 Hz) 47 kΩ (10 Hz) ≈ 8 GΩ (10 Hz)
Input referred noise < 3 μV rms 0.2 μV rms (0–250 Hz) ≈ 0.606 μV rms
(1.5–100 Hz)
0.169 μV rms (0.5–500 Hz)
CMRR 82 dB 110 dB – 134 dB
Maximum resolution
of the ADC
16 bits 24 bits 16 bits 24 bits
Maximum sampling
frequency





13.6 (1700 mAh battery) 6 to 8 (CR1/3 N lithium
ion button-cell battery)
8 (1 Ah lithium battery)
Wireless capability Yes (Wi-Fi) Yes (Bluetooth) Yes (2.4 GHz MSK) Yes (Zigbee)
Latency 12 ms – – 1 ms
Max. transmission range 22 m 10m 3–5 m 5m
Area (length × width) 10.2 cm2 21.7 cm2 (PCB area) 4.76 cm2 44 cm2 (PCB area)
Table 6 Comparison of the proposed instrument’s AFE with state-of-the-art ASICs for biopotential signal acquisition (note that, as
anticipated, a tradeoff exists between ultra-low power consumption (state-of-the-art ASICs) and superior noise performance
(proposed instrument’s AFE))
Parameters [46] [47] [48] [49] [50] This work
Supply 0.2/0.8 V 1 V 1.8 V 1.8 V 3 V ±5 V
Technology 0.18 μm CMOS 0.18 μm CMOS 0.8 μm CMOS 0.18 μm CMOS 0.5 μm CMOS –
Voltage gain 776 V/V 100 V/V 100 V/V 3–100 V/V 10 V/V 1000 V/V
Input impedance ≈ 100 MΩ > 700 MΩ > 7.5 MΩ > 2 GΩ > 100 MΩ 200 GΩ












DC tolerance – Rail-to-rail ±50 mV Rail-to-rail ±50 mV ±85 mV
CMRR 85 dB 60 dB 100 dB 82 dB 120 dB 134 dB
Current ≈ 1 μA 3.5 μA 1.1 μA 11 μA 11.1 μA ≈ 2.5 mA
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The approach adopted in this work was to use a high-
gain (=100 V/V) front-end INA in order to maintain
high CMRR values (=134 dB), and add an active feed-
back integrator to provide high-pass characteristics at
the first stage of the AFE. Next, an active 1st order high-
pass filter and a passive 2nd order low-pass filter were
introduced in the following stages of the AFE in order to
ensure that an adequate suppression of dc electrode off-
sets and high-frequency noise components is achieved in
real time. The merits of this approach are: 1) significant
delays in data processing, which are introduced in the
signal chain by the application of (usually high-order)
digital filtering techniques, are avoided, 2) front-end
amplifier saturation issues are prevented. These issues
often emerge in architectures where a high front-end
gain is applied (to make the weak biosignals detectable
by the front-end electronics and the subsequent ADC
blocks) and analog filtering blocks are absent from the
system design since the signal conditioning process only
takes place in the digital domain, and 3) the introduction
of front-end passive filters, which can lead to the degrad-
ation of the combined (passive filter plus differential
amplifier) apparent CMRR of the front-end due to com-
ponent mismatches [51], is avoided.
Clearly, by assigning the task of electrode dc offset and
high-frequency noise suppression to the analog domain,
we ensure that the real-time character of the system is
maintained. Measured experimental results show that this
aim has been achieved without significantly increasing the
power consumption (at least 8 h of continuous operation
is provided) and size (equal to the size of a business card)
of the designed instrument. The proposed AFE consists of
three active components per channel, namely one INA
and two operational amplifiers, and its current consump-
tion is approximately equal to 2.5 mA. Moreover, all of
the imposed requirements on the AFE design, which were
presented in Table 2, have been satisfied. Further im-
provements in the dc electrode offset rejection capabilities
of the instrument that will enhance its performance in ap-
plications where strong stimulation artefacts affect the
quality of the recorded signals (e.g. DBS, HFS, etc.) can be
accomplished in the digital domain by applying real-time
high-pass filters (see Fig. 14d).
By adding a DAC on the receiver module, we ensure
that the high-quality signals recorded and wirelessly
transmitted by the proposed instrument can be success-
fully recorded and depicted on the computer by com-
mercially available data acquisition systems that are
widely used in clinical settings. This feature renders the
proposed instrument an assistive device that can func-
tionally integrate with existing biosignal recording sys-
tems to offer wireless communication, while maintaining
signal integrity. Indeed, in this study, the biosignals re-
corded and wirelessly transmitted by the proposed
instrument were received by the receiver module and
were successfully depicted on the computer using the
graphical user interface of a commercially available data
acquisition system (Powerlab 16/35, ADInstruments)
widely used by clinicians.
However, having ensured that the proposed instru-
ment can offer high-quality and real-time recordings of
a wide variety of bioelectrical signals, the next step to-
wards rendering it a functional instrument that can fur-
ther facilitate the process of clinical decision-making,
would be to add a wired communication capability in
order to cover the extra need that may exist for high
sampling frequency (the maximum sampling frequency
offered by the ADS1298 chip is 32 kSPS) at the expense
of restricted mobility. In this case, the data sampled by
the ADS1298 chip could be directed from the FPGA to
the computer using the USB 2.0 interface that is pro-
vided by the FPGA module. Finally, the current system
design utilizes only a small fraction of the available
FPGA resources. It is thus clear that there is still ample
room for implementing closed-loop algorithms and
digital FIR filtering blocks to further improve computa-
tional efficiency.
Conclusions
The novel, versatile and state-of-the-art instrument de-
signed, realized and tested both ex vivo and in vivo al-
lows for low-noise, real-time and wireless recording of a
plethora of bioelectrical signals for a bandwidth of 0.5–
500 Hz. Proof of the proposed instrument’s recording
capabilities has been provided and its performance has
been evaluated quantitatively by means of a series of
tests and comparisons with other high-performance bio-
potential acquisition systems (both commercial devices
and academic works were used for this purpose).
Since the proposed instrument is small in size (≈ area of
a business card), battery-powered, wearable and wireless,
it could be used to alleviate the problem of limited mobil-
ity encountered by patients due to the fact that they are
connected to bulky and mains-powered instruments.
Hence, it could allow for continuous monitoring of pa-
tients, thus increasing the biosignal acquisition time and
enhancing the diagnostics of various diseases (such as PD,
essential tremor, epilepsy, ALS, AF, traumatic brain injury,
cardiovascular disease, etc.). Furthermore, since the spec-
tral content of some types of biosignals (e.g. LFPs) varies
among patients [18], the extended passband offered by the
proposed device could lead to a more in-depth analysis of
the spectral content recorded from different patients, fa-
cilitating the personalization of treatment for patients suf-
fering from serious diseases, such as PD.
Moreover, the enhanced recording capabilities of this
instrument, stemming from its low input referred noise
(8 nV/√Hz), have the potential to reveal biomarkers of
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various neurological disorders existing in weak neural
oscillations, previously hidden by the inherent noise of
older biopotential acquisition systems. Hence, this tool
may allow for a deeper understanding of disease mecha-
nisms, physiology and neural processing. Finally, the
proposed instrument can be used for the determination
of features extracted from ECoG/LFP signals that could
serve as biomarkers for regulating and optimizing on-
going DBS. Hence, among others, this work paves the
way for the development of a portable/wearable closed-
loop neurostimulation modality that uses low and
higher-frequency ECoG/LFPs as control signals.
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